HGCO19 is India’s indigenous mRNA vaccine developed by the Pune-based Gennova Biopharmaceuticals. HGCO19 recently received Drug Controller General of India (DCGI) approval for phase I and II of the clinical trials on humans. The vaccine uses the same platform technology as those used by COVID-19 vaccines developed by Pfizer-BioNTech and Moderna. It was developed in collaboration with HDT Biotech Corporation of the US. This vaccine has already demonstrated the safety, immunogenicity and neutralisation antibody activity in animals.
No comments yet.